
From: Raman Nanda [Raman.Nanda@bilcare.com]
Sent: mercredi 21 mai 2008 9:07
To: ENTR PHARMACEUTICALS COUNTERFEIT
Subject: A request

Dear Sirs,

This is a short mail to introduce our Company, and to explain about our serious interest in supporting the European Commission on combating counterfeit drugs, with innovative traceability and mass serialisation solutions.

We also request for time to make our detailed submission on the discussion paper put in the public domain by EMEA, which has just been seen by us and we apologise for the same.

By way of introduction, we would like to mention that Bilcare is already a reputed solution provider and supplier to the global pharmaceutical industry for over a decade in the field of pharma packaging and research as well as for clinical supplies with facilities at Singapore, Wales, Philadelphia and Pune, India.

Dr Praful Naik, Chief Scientific Officer, Bilcare Ltd has on May 14,2008, by a letter from Dr Valerio Reggi, Executive Secretary, been nominated on the IMPACT task force of WHO as a representative of the Organisation of Pharmaceutical Producers' of India. He had made a presentation to the assembled delegates at Singapore in March 08 on Bilcare's technology solutions to prevent counterfeit drugs.

With these credentials in brief, we request for time to make our submission and to present our proposed technology solution to the Commission, and seek a positive answer to this mail.

With warm regards

Raman Nanda
President & CEO
Bilcare Technologies

Bilcare Limited
601 ICC Trade Tower Pune 411016 INDIA
Phone +91 20 3025 7793 Fax +91 20 3025 7703
Cell +91 98220 90425
www.bilcare.com

Disclaimer

This message, including any files transmitted with it, is for the sole use of the intended recipient and may contain information that is confidential, legally privileged or exempt from disclosure under applicable law. If you are not the intended recipient, please note that any unauthorized use, review,

27/05/2008

storage, disclosure or distribution of this message and/or its contents in any form is strictly prohibited. If it appears that you are not the intended recipient or this message has been forwarded to you without appropriate authority, please immediately delete this message permanently from your records and notify the sender. Bilcare makes no warranties as to the accuracy or completeness of the information in this message and accepts no liability for any damages, including without limitation, direct, indirect, incidental, consequential or punitive damages, arising out of or due to use of the information given in this message. Thank you.

Visit us at www.bilcare.com